HK Stock Market Move | EXTRAWELL PHAR(00858) surged over 45% after Yixin's rise, with expected mid-term profit of around HK$105 million and turning loss into profit year-on-year.
Sino Biopharmaceutical (00858) rose more than 45% after announcing its profit. As of the time of writing, it rose by 45.83%, reaching HKD 0.07, with a turnover of HKD 972,700.
EXTRAWELL PHAR (00858) rose over 45% after profit announcement, reaching 0.07 Hong Kong dollars, with a total turnover of 972,700 Hong Kong dollars as of the time of publication.
On the news front, EXTRAWELL PHAR announced that the group expects to achieve a profit of approximately 100 million Hong Kong dollars to 105 million Hong Kong dollars for the six-month period ending September 30, 2024, compared to a loss for the same period ending September 30, 2023. The expected turnaround from loss to profit in this period is mainly due to non-cash items, resulting from the gain on fair value changes in financial assets recognized in the income statement, while a loss was incurred in the same period in 2023 for the same non-cash item.
Related Articles

Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.

Industrial: Hong Kong stock market sentiment index has reached the bottom area.

"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.

Industrial: Hong Kong stock market sentiment index has reached the bottom area.

"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"

RECOMMEND

Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026

Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026

Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026


